Stock Ratings / Health Care / NEOG / financials

CLDX (41) NTLA (33) ORKA (53) LNTH (74) ⌘ Pro Terminal →

Neogen Corporation (NEOG) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$12.26 +1.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Neogen Corporation (NEOG) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $2.68B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEOG)Realized 20D OHLCV Swing Band: ±11.3%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NEOG Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$83.2M (9.6% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $924.2M

FY24

Rev $894.7M

FY25

Rev $870.4M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$870.4M	46.9%	-2.5%	-$7.9M	$83.2M	-0.6%
FY 2024	$894.7M	47.1%	-80%	-$1.09B	$58.2M	-24.5%
FY 2023	$924.2M	46.9%	6.3%	-$9.4M	$35.3M	-0.6%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEOG)

✓Walkthrough of NEOG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEOG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.43%▲ ASCENDING CHANNEL

2026-10-30O $12.15H $12.26L $11.63C $12.26VOL 1.95M

RES: $15.32SUP: $10.22SMA50: $12.23SMA200: $10.42

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEOG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEOG Butterfly Map → + Track NEOG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -2.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NEOG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEOG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEOG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEOG)

Health Care Rank #314 of 1016 ⚔️ CLDX vs NEOG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEOG vs. CLDX, NTLA, ORKA, LNTH)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neogen Corporation (NEOG) ranks #314 by composite RQD confidence (52/100, grade D+) and #216 by equity capitalization ($2.68B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with NEOG at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEOG ACTIVE Neogen Corporation	D+	52/100	—	46.9%	-0.6%	+1.16%	$2.68B	Benchmark Subject
CLDX Celldex Therapeutics Inc.	D-	41/100	—	87.1%	-35.0%	+0.78%	$2.35B	/cldx-vs-neog →
NTLA Intellia Therapeutics Inc.	E	33/100	—	—	-35.0%	-0.68%	$1.85B	/ntla-vs-neog →
ORKA Oruka Therapeutics Inc.	D+	53/100	—	—	-18.8%	+0.71%	$6.40B	/orka-vs-neog →
LNTH Lantheus Holdings Inc.	B	74/100	28.0x	61.1%	20.3%	+0.22%	$6.55B	/lnth-vs-neog →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0000711377

In its most recent audited fiscal period (FY2025, filed 2026-05-31), Neogen Corporation (NEOG) reported GAAP revenue of $870.4M (-2.7% vs. FY2024 revenue of $894.7M , and -5.8% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of $83.2M, and free cash flow of $83.2M (+43.0% YoY). On the balance sheet, NEOG closed FY2025 with $3.36B in total assets against $792.9M in total debt (Altman Z-Score: 1.45, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-05-31	$870.4M	-$7.9M	$83.2M	$83.2M	$3.36B	$792.9M
FY2024 (FY)	2025-05-31	$894.7M	-$1.09B	$58.2M	$58.2M	$4.05B	$889.9M
FY2023 (FY)	2024-05-31	$924.2M	-$9.4M	$35.3M	$35.3M	—	—

3. NEOG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEOG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Neogen Corporation (NASDAQ: NEOG) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $12.26 (+1.16% 1D, market cap $2.68B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, NEOG ranks #314 in composite RQD confidence.

How does NEOG compare to CLDX and NTLA in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NEOG carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 46.9%, and ROIC of -0.6%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $2.35B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEOG?

Per NEOG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0000711377), Neogen Corporation generated $870.4M in revenue (-2.7% YoY), -$7.9M in net income, and $83.2M in free cash flow against $3.36B in total assets and $792.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEOG trading relative to its 50-day, 200-day, and 52-week technical levels?

NEOG last traded at $12.26 (+1.16% on volume of 3,225,858 shares), positioning the stock +0.25% above its 50-day simple moving average ($12.23) and +17.66% above its 200-day simple moving average ($10.42). Across its 52-week range of $5.37 to $14.26, NEOG sits at the 77.5% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($10.87 to $13.65).